Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer
作者单位：Collaborative Innovation Center for Cancer Medicine State Key Laboratory of Oncology in South China Sun Yat-Sen University Cancer Center Department of Biotherapy Sun Yat-Sen University Cancer Center
会议名称：《第十四届全国肿瘤生物治疗大会》
会议日期：2015年
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
关 键 词：cellular immunotherapy cytokine-induced killer cells natural killer cells non-small cell lung cancer benefit
摘 要：Postoperative non-small cell lung cancer(NSCLC) patients require adjuvant therapy to improve their prognosis. In this study, we investigated the efficacy of a sequential combination of cellular immunotherapy(CIT) and chemotherapy for postoperative NSCLC. This retrospective study included 120 postoperative NSCLC patients: 60 cases received only chemotherapy;33 cases received chemotherapy and sequential CIT with cytokine-induced killer(CIK) cells;and 27 cases received chemotherapy and sequential CIT with alternate CIK cells and natural killer(NK) cells. Survival analysis showed significantly higher overall survival rates in the CIT group compared with the control group. Overall survival was higher in patients who received CIT with alternate CIK cells and NK cells than those who received treatment with only CIK cells. Multivariate analysis showed that adjuvant CIT was an independent prognostic factor for overall survival of patients with NSCLC. In subgroup analyses, adjuvant CIT significantly improved the overall survival of patients with less than 60 year old and positive lymph node. In conclusions, these data indicate that adjuvant CIT, especially with combined application of CIK cells and NK cells, is an effective therapeutic approach to prolong survival of patients with NSCLC, particularly for patients ≤60 years old with positive lymph nodes.